Zai Lab (ZLAB) Competitors

Zai Lab (NASDAQ:ZLAB) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Do analysts rate ZLAB or GMAB?

Zai Lab currently has a consensus price target of $47.37, indicating a potential upside of 45.36%. Genmab A/S has a consensus price target of $39.17, indicating a potential upside of 90.82%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Which has better valuation & earnings, ZLAB or GMAB?

Genmab A/S has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$418.33M	8.59	-$334.62M	-$2.49	-13.09
Genmab A/S	$3.12B	4.22	$1.14B	$1.76	11.66

Does the MarketBeat Community favor ZLAB or GMAB?

Zai Lab received 64 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 64.53% of users gave Zai Lab an outperform vote while only 63.02% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Zai Lab	Outperform Votes 231 64.53%	Underperform Votes 127 35.47%
Genmab A/S	Outperform Votes 167 63.02%	Underperform Votes 98 36.98%

Which has more volatility and risk, ZLAB or GMAB?

Zai Lab has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Do institutionals & insiders believe in ZLAB or GMAB?

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 5.0% of Zai Lab shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the media prefer ZLAB or GMAB?

In the previous week, Genmab A/S had 6 more articles in the media than Zai Lab. MarketBeat recorded 19 mentions for Genmab A/S and 13 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.93 beat Genmab A/S's score of 0.78 indicating that Zai Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Genmab A/S	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ZLAB or GMAB more profitable?

Genmab A/S has a net margin of 36.30% compared to Zai Lab's net margin of -76.14%. Genmab A/S's return on equity of 16.78% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-76.14%	-36.97%	-27.10%
Genmab A/S	36.30%	16.78%	13.79%

Summary

Genmab A/S beats Zai Lab on 11 of the 18 factors compared between the two stocks.